文献速递脑血管病

随机ESCAPE-NA1试验中未接受阿替普酶患者奈瑞奈肽对梗死体积影响的因素

Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial.
PubMed 文献 · Stroke · 2024-12-09

该研究是对ESCAPE-NA1随机试验的事后二次分析,纳入446例未接受静脉阿替普酶且接受血管内取栓的急性卒中患者,评估奈瑞奈肽对最终梗死体积的影响。奈瑞奈肽是最终梗死体积较小的强预测因子(校正β系数-0.35 [95%CI,-0.67至-0.02]),且与基线收缩压、麻醉方式及再灌注状态存在交互作用。

要点

  • 奈瑞奈肽与未接受阿替普酶患者最终梗死体积较小强烈相关(校正β系数-0.35 [95%CI,-0.67至-0.02])。
  • 奈瑞奈肽减弱基线收缩压升高(交互P=0.02)和给药后收缩压升高(交互P=0.04)对最终梗死体积的不良影响。
  • 奈瑞奈肽可能减弱再灌注不良对梗死体积的有害影响(交互P=0.08,边缘显著)。

核心结论

  • 在未同时接受阿替普酶治疗的患者中,奈瑞奈肽治疗与最终梗死体积较小强烈相关。
  • 在预后因素较差的患者中,梗死体积的减小幅度更大。

研究设计与样本

  • ESCAPE-NA1为多中心随机试验,纳入基线Alberta卒中项目早期CT评分>4、接受血管内取栓的急性卒中患者,随机接受静脉奈瑞奈肽或安慰剂。
  • 本分析为试验数据的事后二次分析,纳入未接受静脉阿替普酶的患者,共446例(奈瑞奈肽组219例,安慰剂组227例),来自总入组1105例。
  • 最终梗死体积在24小时非增强CT或弥散加权磁共振成像上手动分割。
  • 采用以立方根转换的梗死体积为因变量的多变量线性回归识别预测因子,并通过在模型中纳入交互项检验治疗与预测因子的交互作用。

主要发现

  • 奈瑞奈肽是梗死体积较小的强预测因子(校正β系数-0.35 [95%CI,-0.67至-0.02])。
  • 其他梗死体积较小的预测因子包括:高血压病史、多期CT血管造影上良好的软脑膜侧支充盈、大脑中动脉闭塞相较于颈内动脉闭塞、较低的基线美国国立卫生研究院卒中量表评分、较低的基线收缩压、较低的基线血清葡萄糖、较短的发病至随机化时间以及较高的Alberta卒中项目早期CT评分。
  • 存在治疗与收缩压及治疗与麻醉的交互作用:奈瑞奈肽减弱基线收缩压升高(交互P=0.02)和给药后收缩压升高(交互P=0.04)以及使用全身麻醉(交互P=0.06)对最终梗死体积的不良影响。
  • 观察到与再灌注状态的边缘显著交互作用,奈瑞奈肽可能减弱再灌注不良对梗死体积的有害影响(交互P=0.08)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the ESCAPE-NA1 trial (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke), treatment with nerinetide was associated with a smaller infarct volume among patients who did not receive intravenous alteplase. We assessed the effect of nerinetide on the surrogate imaging outcome of final infarct volume in patients who did not receive intravenous alteplase and explored predictors of outcome and modifiers of nerinetide's effect on infarct volume. METHODS: ESCAPE-NA1 was a multicenter, randomized trial in which patients with acute stroke with a baseline Alberta Stroke Program Early CT Score >4, undergoing endovascular thrombectomy, were randomized to receive intravenous nerinetide or placebo. Patients not receiving intravenous alteplase were included in this post hoc secondary analysis of the trial data. Final infarct volume was manually segmented on 24-hour noncontrast computed tomography or diffusion-weighted magnetic resonance imaging. Predictors of final infarct volume were identified using multivariable linear regression with cubic-root-transformed infarct volume as the dependent variable. Evidence of treatment-by-predictor interaction was tested by including interaction terms in the model. RESULTS: Four hundred forty-six patients (219 who received nerinetide and 227 who received a placebo) out of a total of 1105 enrolled patients were included in this secondary post hoc analysis of the randomized ESCAPE-NA1 trial. Nerinetide was a strong predictor of smaller infarct volume (adjusted β coefficient, -0.35 [95% CI, -0.67 to -0.02]). Other predictors of smaller infarct volume were history of hypertension, good pial collateral filling on multiphase computed tomography angiography, a middle cerebral artery occlusion compared with an internal carotid artery occlusion, lower baseline National Institutes of Health Stroke Scale score, lower baseline systolic blood pressure, lower baseline serum glucose, shorter onset-to-randomization time, and higher Alberta Stroke Program Early CT Score. There was evidence of a treatment-by-systolic blood pressure and treatment-by-anesthesia interaction: nerinetide attenuated the negative effects of elevated baseline (Pinteraction=0.02) and postdose (Pinteraction=0.04) systolic blood pressure and use of general anesthesia (Pinteraction=0.06) on final infarct volume. We observed a marginally significant interaction with reperfusion status, such that nerinetide may attenuate the harmful effect of poor reperfusion status on infarct volume (Pinteraction=0.08). CONCLUSIONS: Nerinetide treatment was strongly associated with smaller final infarct volumes among patients not cotreated with alteplase. The reduction in infarct volume was greater among patients with poor prognostic factors. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02930018.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Ospel JM, Goyal M, Menon BK, et al. Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial. Stroke. 2024. PMID: 39648909. doi:10.1161/STROKEAHA.124.048601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。